Sanofi Extends Cancer Ambitions With IL-2 Drug And Keytruda Combination
Seeking Cancer Blockbuster To Match Dupixent Success
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.
You may also be interested in...
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track.
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.